Biotinylated Human LAG3/CD223 Protein, Active
Beta LifeScience
SKU/CAT #: BLK-01795P-100UG

Biotinylated Human LAG3 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
Biotinylated Human LAG3/CD223 Protein, Active
Beta LifeScience
SKU/CAT #: BLK-01795P-100UG
Collections: Car-nk targets proteins, High-quality recombinant proteins
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Description | Recombinant Biotinylated Human LAG3/CD223 Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus.It contains Leu23-Gly434. |
Purity | > 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC |
Accession | P18627 |
Target Symbol | LAG3/CD223 |
Synonyms | CD223; FDC; LAG3; LAG-3; sLAG-3 |
Species | Human |
Expression System | HEK293 |
Tag | C-His-Avi |
Expression Range | Leu23-Gly434 |
Mol. Weight | The protein has a predicted MW of 47.3 kDa. Due to glycosylation, the protein migrates to 55-65 kDa based on Tris-Bis PAGE result. |
Form | Lyophilized |
Formulation | Lyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
Endotoxin | Less than 1EU per ug by the LAL method. |
Activity | Immobilized Anti-LAG3 Antibody, hFc Tag at 2ug/ml (100ul/well) on the plate. Dose response curve for Biotinylated Human LAG3, His Tag with the EC50 of 12.7ng/ml determined by ELISA. Contact us for detailed testing images. |
Storage | Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
Shipping | Shipped at ambient temperature. |
Gene Background | LAG-3, is a protein which in humans is encoded by the LAG3 gene, which is a cell surface molecule with diverse biologic effects on T cell function. It is an immune checkpoint receptor and as such is the target of various drug development programs by pharmaceutical companies seeking to develop new treatments for cancer and autoimmune disorders. |